HOME >> BIOLOGY >> NEWS
A tNOX-based protocol for early detection of lung cancer in smokers and nonsmokers

CHICAGO -- Lung cancer is a formidable disease. While it is one of the most preventable cancers, with the vast majority of 160,000 annual deaths in the United States due to smoking, it is invariably difficult to find early when it is most amenable to treatment. As a result, it remains the top cancer killer in the nation.

But a new test for the early detection of lung cancer that involves measuring levels of a certain protein may provide hope for thousands of smokers worldwide. While the findings are preliminary and involve a small group of subjects, the researchers see their early results as extremely promising.

Results were presented at the first meeting on Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.

A team led by Dorothy M. Morre, Ph.D., professor of foods and nutrition at Purdue University in West Lafayette, Indiana, and D. James Morre, Ph.D., distinguished professor of medicinal chemistry at Purdue, wanted to come up with a robust lung cancer screening procedure for people who smoke.

"We'd like to have a means of detecting lung cancer early in individuals who smoke with a low incidence of false positives," Dorothy Morre said. "There's apparently no good method of finding this and there is a lot of interest at the National Cancer Institute in developing such a protocol."

The Morres -- along with colleagues at Purdue, NOX Technologies, Inc., also in West Lafayette, and at Mount Sinai Medical Center in New York -- focused their efforts on a protein called tNOX, a member of a family of proteins that are involved in cell growth. Normal cells express the NOX enzyme only when they are dividing in response to growth hormone signals. In contrast, cancer cells have gained the ability to express NOX activity at all times. This overactive form of NOX, known as tNOX for tumor-associated NOX has long been assumed to be vital for the growth of cancer cell
'"/>

Contact: Warren Froelich
froelich@aacr.org
215-440-9300
American Association for Cancer Research
13-Sep-2006


Page: 1 2 3

Related biology news :

1. Newborn hearing screening programs may benefit from the standardization of testing protocols
2. The American Physiological Society publishes resource book for animal exercise protocols
3. New protocol tracks how land use influences the way streams work
4. New cyber security protocol for online banking, and more
5. An early ape shows its hand
6. Purdue-IU researchers explore new method for early disease diagnosis
7. Nearly 90 percent of babies receive recommended newborn screening tests
8. A first-principles model of early evolution
9. New blood test might offer early warning of deep belly fat
10. Marine worm opens new window on early cell development
11. Modular leukemia drug shows promise in early testing

Post Your Comments:
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
(Date:7/28/2015)... A n ew UK ... and commercialising innovative medicines to transform patient quality of life ... management team; blue chip investor ... Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces that ... from blue chip institutional investors and simultaneously acquired a portfolio ...
(Date:7/28/2015)... ... July 29, 2015 , ... Strong Animals™ announced today that research ... operation and presented at the ADSA-ASAS Joint Annual Meeting held July 12-16 in Orlando, ... cows and increased milk fat content. Also, feed containing Stay Strong™ for Dairy Cows ...
(Date:7/28/2015)... ... July 29, 2015 , ... The new Xsample 530 sample changer for vials ... wide range of liquid viscosities – from less than 12,000 mPas (internal air) up to ... , What immediately catches the eye about Xsample 530 is its removable magazine, which ...
(Date:7/28/2015)... 28, 2015  PDL BioPharma, Inc. (PDL, or the ... Company will release its second quarter 2015 financial results ... August 5, 2015, after market close. PDL,s management will ... 4:30 p.m. Eastern Time to discuss the financial results. ... available via the webcast link on the PDL website. ...
Breaking Biology Technology:Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2New Moves in Automatic Sample Handling: Introducing Xsample 530 2PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
Cached News: